Trial reportBMC anesthesiology2025
Optimal analgesia after laparoscopic total hysterectomy with pre-pneumoperitoneum phrenic nerve block using different ropivacaine concentrations: randomized controlled trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPost-laparoscopic shoulder pain (PLSP) is common after total laparoscopic hysterectomy and can negatively affect recovery. Ultrasound-guided right phrenic nerve block is effective in preventing PLSP, but the optimal concentration of ropivacaine and the best timing for nerve block remain unclear.
methodsIn this randomized controlled trial, 198 patients undergoing laparoscopic total hysterectomy were allocated into six groups (A1-A3: pre-pneumoperitoneum PNB; B1-B3: PNB at skin closure; n = 33 each), receiving 6 mL of 0.25%, 0.3%, or 0.375% ropivacaine. The primary outcomes were the incidence of PLSP within 72 h and visual analog scale (VAS) pain scores at 0.5 h (T1), 6 h (T2), 24 h (T3), 48 h (T4), and 72 h (T5). Secondary outcomes included rescue analgesic use and postoperative nausea and vomiting (PONV). Multiple comparisons were Bonferroni-corrected (significance: adjusted P < 0.05).
resultsBaseline characteristics, including age, Body Mass Index (BMI) and American Society of Anesthesiologists (ASA) physical status classification, were comparable among all groups (P > 0.05). The incidence of PLSP was lowest in group A3 (pre-pneumoperitoneum, 0.375% ropivacaine) at 6.1% (2 of 33), significantly lower than in group A1 (45.5%, χ² = 13.390, P < 0.001; Bonferroni-adjusted P = 0.003) and group A2 (30.3%, χ² = 6.519, P = 0.011; adjusted P = 0.033). In group B3 (skin closure, 0.375% ropivacaine), the PLSP rate was 24.2% (8 of 33), showing marginal significance compared to B1 and B2 (adjusted P = 0.051). At 24 h (T3), VAS scores in A3 were significantly lower than in A1, B1, and B2 (P < 0.05; Bonferroni-adjusted P = 0.10 with three comparisons). At 48 h (T4), scores in A3 remained significantly lower than in B1 and B2 (P < 0.05; adjusted P = 0.10 with two comparisons). No significant differences were observed at T1, T2, or T5 (P > 0.05). Safety outcomes showed no significant differences in intraoperative drug use, rescue analgesic requirement, or PONV incidence (P > 0.05), and no local anesthetic toxicity or serious adverse events were reported.
conclusionPre-pneumoperitoneum ultrasound-guided right phrenic nerve block with 0.375% ropivacaine reduced PLSP incidence to 6.1% (adjusted P < 0.05), improved 24–48 h pain control (trend after adjustment), and was well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.